GlassScriptPhysician profile
John Damien Harding
NPI 1144218835
$20,631.30
in general payments reported to CMS, 2019-2025
24 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
See the full distribution for Clinical Cardiac Electrophysiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,613 · 2021: $2,657 · 2022: $622 · 2023: $419 · 2024: $1,731 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500 · Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
| Food and Beverage | $881.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $14,441.50 | 2019-2020 | |
| Medtronic, INC. | $3,152.87 | 2021-2025 | V-Loc 180, Linq II |
| Biosense Webster, INC. | $796.72 | 2021-2023 | Nuvision Ice Catheter |
| Abbott Laboratories | $414.96 | 2019-2025 | Jot Dx, Ensite |
| Boston Scientific Corporation | $239.92 | 2019-2025 | Watchman Access System, Watchman Flx, Farapulse |
| E.R. Squibb & Sons, L.L.C. | $231.45 | 2019-2025 | Eliquis, Camzyos |
| Abiomed | $206.91 | 2019-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $152.61 | 2020-2024 | |
| Atricure, INC. | $126.11 | 2019-2024 | |
| Pfizer INC. | $120.84 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $116.84 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $113.09 | 2021-2025 | Verquvo |
| Amgen INC. | $103.99 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $81.93 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $80.17 | 2019-2023 | Farxiga, Brilinta |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $71.84 | 2022-2024 | Uptravi, Opsumit |
| Regeneron Healthcare Solutions, INC. | $46.52 | 2019 | |
| Shockwave Medical, INC | $27.98 | 2020-2022 | |
| Novo Nordisk INC | $27.86 | 2023 | Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $24.92 | 2024 | Injectafer |
| Ferring Pharmaceuticals INC. | $19.61 | 2024 | Adstiladrin |
| Cardiva Medical, INC. | $16.56 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $16.10 | 2023 | Arcalyst |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.